The Foundation’s Scientific Advisory Board (SAB) represents a distinguished group of leaders in CLL research. The SAB defines research priorities focused on critical unmet needs in CLL and oversees the funding process—from issuing requests for applications through award selection—ensuring that supported projects reflect the highest standards of scientific integrity, innovation, and potential impact.

Michael Keating, M.B., B.S.
Professor Emeritus, Department of Leukemia
The University of Texas MD Anderson Cancer Center

William Wierda, M.D., Ph.D.
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center

William Plunkett, Ph.D.
Professor, Department of Experimental Therapeutics
The University of Texas MD Anderson Cancer Center

Nicholas Chiorazzi, M.D.
Professor, Institute of Molecular Medicine
Feinstein Institutes for Medical Research, Northwell Health

Steve Winfield
CLL Global Board President